Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Objective To evaluate pathological complete response as a surrogate endpoint for disease-
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Background HER2-targeted treatments have improved outcomes in patients with HER2-
positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some …

Purpose Placing clips in nodes with biopsy-confirmed metastasis before initiating
neoadjuvant therapy allows for evaluation of response in breast cancer. Our goal was to …

Gene-expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer …

Systemic therapies for operable breast cancer patients have improved outcomes and have
thus become standard treatments. Recently, new molecular target drugs and regimens are …

Abstract Human Epidermal Growth Factor Receptor 2-positive breast cancer (HER2+ BC) is
defined by increased amplification of the ERBB2/neu oncogene and/or overexpression of its …

Background Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy
when combined with the established HER2-directed antibody trastuzumab in breast cancer …

The management of human epidermal growth factor receptor (HER2)–positive breast cancer
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …